When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved for psoriasis focused on patient populations with infestation of these difficult-to-treat body regions.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
Opicapon: double benefit for motor function and sleep in Parkinson’s disease
- Colorectal cancer
Is exercise better than medication?
- Itching in primary biliary cholangitis
When the skin becomes agony
- TREATswitzerland Register
Evaluation of system therapies for AD
- Cardiogenic shock - 2025 update
Between standardization, team processes and targeted cycle support
- Collagenoses
Scleroderma – Current recommendations for diagnosis and therapy 2025
- Multiple sclerosis
Avoiding the nocebo trap with natalizumab biosimilars
- COPD and comorbidities